In a recent study, the circulating concentration of GDF-15 was measured at baseline (n = 1734) and at 12 months (n = 1517) in patients randomised in the Valsartan Heart Failure Trial (Val-HeFT) [14]. Here, GDF15 is linked to heart failure.